Dan Paterson - 16 May 2025 Form 4 Insider Report for Verastem, Inc. (VSTM)

Role
President and CEO, Director
Signature
/s/ Daniel Calkins, Attorney in Fact
Issuer symbol
VSTM
Transactions as of
16 May 2025
Net transactions value
-$477,044
Form type
4
Filing time
20 May 2025, 19:52:32 UTC
Previous filing
07 May 2025
Next filing
20 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Paterson Dan President and CEO, Director C/O VERASTEM, INC.,, 117 KENDRICK ST., SUITE 500, NEEDHAM /s/ Daniel Calkins, Attorney in Fact 20 May 2025 0001563202

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VSTM Common Stock Award $0 -25,000 -6.3% $0.000000 370,659 16 May 2025 Direct F1
transaction VSTM Common Stock Award $0 -150,000 -22% $0.000000 520,659 16 May 2025 Direct F2
transaction VSTM Common Stock Sale $477,044 -58,677 -11% $8.13 461,982 20 May 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on August 2, 2023. 25,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the U.S. Food and Drug Administration (the "FDA") of a new drug application ("NDA") for a product which contains avutometinib in combination with defactinib had occurred.
F2 The reported securities were subject to a performance RSU award that was granted on June 18, 2024. 150,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the FDA of an NDA for the Company's combination therapy of avutometinib and defactinib for the treatment of low-grade serous ovarian cancer had occurred.
F3 The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.